ReviewEuropean cardiology2022
Valvular Heart Disease in Patients with Chronic Kidney Disease.
Review in European cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- The association of peritoneal dialysis and hemodialysis on mitral and aortic valve calcification associated mortality: a meta-analysis.Scientific reports · 2024Pooled it
- Serum sclerostin in vascular calcification in CKD: a meta-analysis.Renal failure · 2023Pooled it
- Effect of serum albumin on cardiac-related events in end-stage kidney disease with mitral regurgitation initial hemodialysis.Medicine · 2026Article
- Deep Learning-Enabled Screening of Chronic Kidney Disease from Echocardiography.medRxiv : the preprint server for health sciences · 2026Article
- Two Faces of Mitral Stenosis: Uncovering Structural and Hemodynamic Signatures of Rheumatic and Mitral Annular Calcification-Induced Disease.Journal of the American Heart Association · 2026Article
- Cardiovascular Disease in Advanced Chronic Kidney Disease in a Tertiary Institution, Johannesburg, South Africa.International journal of nephrology and renovascular disease · 2026Article
- Functional Mitral Regurgitation following Successful Living Donor Kidney Transplant: The VINTAGE Study.Cardiorenal medicine · 2026Article
- Uromodulin as a genetically anchored biomarker stratifies time to valve intervention in aortic regurgitation.Frontiers in cardiovascular medicine · 2026Article
- Accelerated biological aging and incident degenerative valvular heart disease: Findings from 408,783 UK Biobank participants.International journal of cardiology. Heart & vasculature · 2025Article
- Combining Minimally Invasive Mitral Valve Replacement with Kidney Transplantation: A Pioneering Case.The American journal of case reports · 2025Article
- Burden of Valvular Heart Disease Diagnosed on Protocolised Echocardiography for Waitlist Placement in End-Stage Kidney Patients.Nephrology (Carlton, Vic.) · 2025Article
- Chronic kidney disease and valvular heart disease: State of the art.Physiological reports · 2025Review
- Mitral Annular Calcification: Natural History, Prognosis, and Clinical Outcomes.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- [The association between biological aging markers and valvular heart diseases].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Article
- Vitamin K-Dependent Proteins as Predictors of Valvular Calcifications and Mortality in Hemodialysis Patients.Biomedicines · 2024Article
- Rethinking Mitral Annular Calcification and Its Clinical Significance: From Passive Process to Active Pathology.Journal of personalized medicine · 2024Review
- Racial, ethnic, and sex disparities in the utilization and outcomes of tricuspid valve surgery.Annals of medicine and surgery (2012) · 2024Article
- In-hospital outcomes of transcatheter aortic valve replacement in patients with chronic and end-stage renal disease: a nationwide database study.BMC cardiovascular disorders · 2024Article
- Left atrial Thrombus formation after discontinuation of anticoagulation in patient with severe bioprosthetic mitral stenosis.BMC cardiovascular disorders · 2023Review
- Hypoxia-inducible factor activation promotes osteogenic transition of valve interstitial cells and accelerates aortic valve calcification in a mice model of chronic kidney disease.Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valvular heart disease (VHD) is highly prevalent in patients with chronic kidney disease (CKD) from the early stages to end-stage renal disease (ESRD). Aortic and mitral valves are the most frequently affected, leading to aortic valve and/or mitral annular calcification, which, in turn, causes either valve stenosis or regurgitation at an accelerated rate compared with the general population. Tricuspid regurgitation is also prevalent in CKD and ESRD, and haemodialysis patients are at an increasingly high risk of infective endocarditis. As for pathophysiology, several mechanisms causing VHD in CKD have been proposed, highlighting the complexity of the process. Echocardiography constitutes the gold standard for the assessment of VHD in CKD/ESRD patients, despite the progress of other imaging modalities. With regard to treatment, the existing 2017 European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines on the management of VHD addressing patients with normal kidney function are also applied to patients with CKD/ESRD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.